Panhypopituitarism 2015 Billable Thru Sept 30/2015 Non-Billable On/After Oct 1/2015 ICD-9-CM 253.2 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 253.2 should only be used for claims with a date of service on or before September 30, 2015.
Panhypopituitarism ICD-9-CM 253.2 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 253.2 should only be used for claims with a date of service on or before September 30, 2015. For claims with a date of service on or after October 1, 2015, use an equivalent ICD-10-CM code (or codes).
ICD-9 Code 253.2 Panhypopituitarism. ICD-9 Index; Chapter: 240–279; Section: 249-259; Block: 253 Disorders of the pituitary gland and its hypothalamic control; 253.2 - Panhypopituitarism
(pan-HY-poh-pih-TOO-ih-tuh-rih-zum) A rare condition in which the pituitary gland stops making most or all hormones. Pituitary hormones help control the way many parts of the body work.
E29. 1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM E29.
ICD-10 | Diabetes insipidus (E23. 2)
E23. 0 - Hypopituitarism. ICD-10-CM.
Table 1ICD-10 codeDiagnosisE23.0xaHypopituitarismE23.1Drug-induced hypopituitarismE23.3Hypothalamic dysfunction, not elsewhere classifiedE23.6xaOther disorders of pituitary gland8 more rows•Feb 9, 2017
Diabetes insipidus is caused by problems with a chemical called vasopressin (AVP), which is also known as antidiuretic hormone (ADH). AVP is produced by the hypothalamus and stored in the pituitary gland until needed. The hypothalamus is an area of the brain that controls mood and appetite.
E23. 2 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
Central diabetes insipidus. Damage to the pituitary gland or hypothalamus from surgery, a tumor, head injury or illness can cause central diabetes insipidus by affecting the usual production, storage and release of ADH . An inherited genetic disease also can cause this condition.
It is also known as type i pituitary dwarfism. Human hypophysial dwarf is caused by a deficiency of human growth hormone during development. A genetically heterogeneous disorder caused by hypothalamic gnrh deficiency and olfactory nerve defects.
The 2022 edition of ICD-10-CM E23.0 became effective on October 1, 2021.
A condition of diminution or cessation of secretion of one or more hormones from the anterior pituitary gland. This may result from surgical or radiation ablation, non-secretory pituitary neoplasms, metastatic tumors, infarction, pituitary apoplexy, infiltrative or granulomatous processes, and other conditions.
Diminution or cessation of secretion of one or more hormones from the anterior pituitary gland (including lh; follicle stimulating hormone; somatotropin; and corticotropin). This may result from surgical or radiation ablation, non-secretory pituitary neoplasms, metastatic tumors, infarction, pituitary apoplexy, infiltrative or granulomatous processes, and other conditions.
A form of dwarfism caused by complete or partial growth hormone deficiency, resulting from either the lack of growth hormone-releasing factor from the hypothalamus or from the mutations in the growth hormone gene (gh1) in the pituitary gland. It is also known as type i pituitary dwarfism.
Infiltrative diseases such as hemochromatosis, sarcoidosis, and histiocytosis may be associated with the development of panhypopituitarism. Pituitary apoplexy is a medical emergency and is due to acute ischaemic infarction or hemorrhage of the pituitary gland. Pituitary apoplexy may occur in the presence of a pituitary adenoma ...
Panhypopituitarism symptoms. It appears that that 75% of the pituitary needs to be damaged to result in panhypopituitarism. Clinical features of panhypopituitarism are diverse and may be subtle and ill-defined or severe with the acute presentation.
Other causes of panhypopituitarism include injury to the pituitary gland following traumatic brain injury or iatrogenically during surgery or cranial irradiation. Inflammatory conditions of the pituitary may also be responsible for the occurrence of panhypopituitarism.
Presenting signs and symptoms may be linked to that of a deficiency of pituitary hormone, mass effects in the presence of pituitary tumors, and/or features of the causative disease. Mass effects include visual field defects known as bitemporal hemianopsia. Visual field defects may also occur unilaterally. Patients may also present with headaches, secondary to the mass lesions. Manifestations that suggest congenital anterior hypopituitarism include micropenis, midline defects, optic atrophy, hypoglycemia, and poor growth 4). The presence of a secretory pituitary tumor may result in features of hormone excess for the particular hormone produced by a tumor while other pituitary hormones may be deficient 5).
The posterior pituitary produces vasopressin (antidiuretic hormone [ADH]) and oxytocin. The presence of hypopituitarism is associated with increased mortality due to increased cardiovascular and respiratory diseases, and early diagnosis is important to prevent further morbidity due to the subtle presentation 2).
The diagnosis of hypopituitarism is made by measuring basal hormone levels in the morning fasting status or performing stimulation tests if necessary. Six anterior pituitary hormones (GH, prolactin, LH, FSH, TSH, and ACTH) as well as target hormones can be measured via sensitive and reliable immunoassay techniques. Other pituitary hormones except GH and ACTH deficiency can be diagnosed with basal hormone measurement. Hence, combined pituitary function tests (i.e., the cocktail test) is rarely used [17].
Hypopituitarism is defined as the total or partial loss of anterior and posterior pituitary gland function that is caused by pituitary or hypothalamic disorders [1]. The incidence rate (12 to 42 new patients per million per year) and the prevalence rate (300 to 455 patients per million) seems to underestimate the actual incidence of this disorder given that as many as 30% to 70% of patients with brain injury exhibit symptoms of diminished hormone secretion from their pituitary gland [2]. Additionally, factors such as the cause of hypopituitarism, age of onset, and the speed and degree of loss of hormone secretion may affect the clinical manifestations of hypopituitarism. For example, although a partial hormone deficiency that progresses slowly may go undetected for years, the sudden and complete loss of hormone secretion results in an emergency situation that requires immediate medical attention [2]. The treatment of hypopituitarism typically involves a replacement of the deficient hormone but care must be taken because several studies have reported an increased incidence of cardiovascular disorders and number of deaths among these patients [3]. Additionally, a significant proportion of patients who have been treated for a hormone deficiency suffer from more or less vague discomforts and a reduced quality of life [4]. The present review will describe the general aspects of hypopituitarism focusing on the limitations of the stimulation test and hormone replacement treatment.
Damage to the pituitary stalk often occurs after the head and/or neck injury accompanying a fracture of the bones surrounding the sella turcica [5]. Additionally, tumors near the sella turcica may press against the stalk and damage it. The stalk is often accidentally severed during surgery on a sellar or parasellar mass [1]. Central nervous system disorders involving the hypothalamus, such as craniopharyngioma and germ cell tumor, may also cause hypopituitarism by impeding the secretion of releasing hormone from hypothalamus [1]. Depending on the anatomical location of the lesion, patients may manifest symptoms consistent with a single hormone deficiency, panhypopituitarism, or a posterior pituitary failure (diabetes insipidus) [1]. Recently, the prevalence of idiopathic hypopituitarism has increased but it is thought that these cases are likely due to a severed stalk resulting from traumatic brain injury (TBI) or hypothalamic damage [1]. Similarly, the incidence of hypopituitarism after a TBI seems to be more frequent than previously thought as the prevalence rate ranges from 30% to 70% based on the patients' charateristics and the types of diagnostic tests [2]. The most common problem associated with hypopituitarism is a GH deficiency. Following TBI, the early diagnosis of a hormone deficiency has an important impact on their degree of recovery from TBI [2]. Additionally, it has been demonstrated that hormone replacement therapy improves rehabilitation outcome and the quality of life of a patient [9]. Whereas approximately half of the patients who exhibit hypopituitarism within 6 months of a TBI recover normal pituitary function within 1 year, some patients with normal hormone levels after a TBI develop new hormone deficiency after 12 months [2]. Early posttraumatic panhypopituitarism generally persists [2]. Thus, it is recommended to re-evaluate anterior pituitary function and quality of life after approximately 6 to 12 months of an injury [2]. However, it is controversial regarding the most appropriate early evaluation time after this type of injury.
The most common causes of primary hypopituitarism are pituitary adenoma and complications from surgery or radiation therapy for the treatment of pituitary adenoma [5]. In these situations, the diameter of the pituitary adenoma is 1 cm or larger and, the onset of hypopituitarism is usually slow unless the patient suffers from a pituitary apoplexy whose symptoms occur within several hours or a few days [5]. Several putative mechanisms of hormone deficiency include the application of direct pressure onto or damage to the normal tissues surrounding the tumor, mechanical compression of the portal veins by the pituitary stalk, raised intrasellar pressure, and focal necrosis due to the prolonged portal vein interruption [5]. Furthermore, inflammatory hypophysitis (including various types of autoimmune hypophysitis), which has an unknown etiology and presents with symptoms that are difficult to differentiate from those associated with a tumor, is another possible cause of hypopituitarism [5]. Although this cause is rare, it is known to exhibit clinical features such as the isolated or combined lack of adrenocorticotropic hormone (ACTH), thyroid stimulating hormone (TSH), gonadotropin, and/or growth hormone (GH) [5].
Health problems such as metabolism disorders, systemic diseases, and stress can all be related to selective pituitary hormone deficiencies. The influence of stress seems to manifest via inflammatory cytokines such as interleukin 1 (IL-1) and IL-6, which have severely suppressive effects on thyroid releasing hormone (TRH) and gonadotropin releasing hormone (GnRH) levels while at the same time stimulating the secretion of corticotropin releasing hormone (CRH). This is one possible explanation for euthyroid sick syndrome or hypothalamic amenorrhea because when the original stress is eliminated, these suppressive effects are also ameliorated. In contrast, inflammatory or invasive diseases that destroy the hypothalamus may explain the infrequent recovery of neuroendocrine function in patients suffering from these disorders even after the underlying disease is treated [1].
It is advisable to re-evaluate pituitary gland functionality 2 to 3 months after an operation because, although most hypopituitarism symptoms are irreversible, a patient may recover some of level of function [4]. When a pituitary hormone deficiency occurs following a TBI, it is also necessary to re-evaluate function after some time has elapsed. In addition, of the patients with prolactinoma that are treated with a dopamine agonist, two-thirds recover pituitary gland function [22], which indicates that sporadic re-evaluations of pituitary gland function can prevent unnecessary replacement therapy. Similarly, children who exhibit an idiopathic single GH deficiency or severe GH deficiencies due to radiotherapy require re-evaluation of their GH function when they reach maturity [4].
Primary hypopituitarism is caused by disorders of the pituitary gland itself and may be due to the loss, damage, or dysfunction of pituitary hormone-secreting cells. On the other hand, secondary hypopituitarism is the result of diseases of the hypothalamus or pituitary stalk interrupting the nerve or vascular connections to the pituitary gland, thereby reducing the secretion of the pituitary hormones (Table 1). Reductions in hormone secretion in the posterior pituitary gland may largely be due to failures in hormone synthesis or secretion from the hypothalamus while decreased hormone secretion in the anterior pituitary gland may be due to deficiencies in the activity of one or more of the neurohormones secreted from the hypothalamus [1].